OUR COMMITMENT TO CONTINUED TREATMENT FOR TRIAL PARTICIPANTS

At AbbVie, we focus on discovering, developing, and delivering innovative medicines and treatments where we have proven expertise and can make an impact to patients.

A critical component of our product development is conducting clinical trials to evaluate the safety and efficacy of investigational treatments. AbbVie recognizes the significant contribution patients make by participating in our clinical trials and is committed to providing continued treatment with our investigational treatments to participants in our clinical trials considering the following:

- The patient has completed an AbbVie-sponsored clinical trial and continues to benefit from the treatment;
- The patient has a serious or life-threatening medical condition which requires continued administration of the AbbVie investigational treatment;
- The investigator considers AbbVie investigational treatment to be the best treatment option at the time and the patient consents to continued treatment;
- AbbVie can continue to supply the investigational treatment and does not have safety or efficacy concerns based on available data;
- Access is allowed per local laws and regulations; and
- The investigational treatment is not commercially available and/or reasonably accessible to the patient (such as through insurance or reimbursement coverage, or a local commercial access mechanism).

Following the determination of the appropriate medical treatment by the investigator, AbbVie will work closely with investigators to discuss all circumstances unique to individual patient needs.